Compare Eli Lilly And Co (LLY) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Lumen Technologies Inc — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Lumen Technologies Inc trades at $5.3 (market cap $5.73B). The key difference: Eli Lilly And Co is far larger — about 181.5× Lumen Technologies Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Lumen Technologies Inc for 40 Days on average.
| LLY | LUMN | |
|---|---|---|
Market Cap | $1.04T | $5.73B |
Volume | 3,064,878 | 17,079,799 |
Sector | Health | Media |
52-Week High | $1.28K | $11.83 |
52-Week Low | $799.57 | $5.53 |
Typical Hold Time | 93 Days | 40 Days |
Enterprise Value | $1.09T | $17.35B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
LUMN trades at $5.20, down 12.01% in 24 hours, reflecting bearish technical signals and negative profitability. Revenue declined to $12.40B in 2025 with a net loss of $1.74B, though recent product launches like Intelligent Internet target AI-driven growth. The stock faces high debt levels at $17.49B long-term, while analyst consensus is predominantly Hold (60.71%) with a Reduce rating average.
The outlook remains challenged by legacy revenue declines and substantial debt, but strategic pivots to AI networking offer speculative upside. Key risks include persistent losses and competitive pressures, requiring careful monitoring of cash flow and execution on new initiatives for any sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
